Calidi Biotherapeutics Advances BiTE Technology for Solid Tumors via RedTail Platform
Event summary
- Calidi Biotherapeutics presented data on its novel BiTE approach using the RedTail platform at the 2026 AACR-IO Conference.
- RedTail platform demonstrated the ability to express both a functional BiTE and IL-15 superagonist in the tumor microenvironment.
- CLD-401, the lead candidate from the RedTail platform, is in IND-enabling studies with an anticipated IND application submission by the end of 2026.
- Calidi is pursuing strategic partnerships to accelerate clinical development of the RedTail platform.
The big picture
Calidi Biotherapeutics is addressing a critical gap in oncology by leveraging its RedTail platform to deliver BiTEs effectively in solid tumors, a area where traditional BiTEs have failed. The company's approach combines TME remodeling with targeted T-cell activation, positioning it at the forefront of next-generation cancer therapies. The strategic pursuit of partnerships underscores the potential scale and market impact of this technology.
What we're watching
- Clinical Validation
- Whether the RedTail platform can overcome historical limitations of BiTEs in solid tumors through simultaneous TME remodeling and T-cell activation.
- Regulatory Timeline
- The pace at which Calidi can submit and receive approval for the IND application for CLD-401 by the end of 2026.
- Partnership Strategy
- How strategic partnerships will impact the acceleration of clinical development and broadening of the RedTail platform's impact.
Related topics